HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Registry report: International Society for Heart and Lung Transplantation.

AbstractOrthotopic heart transplantation continues to be a highly successful therapy for end-stage cardiac disease. Recent advances have extended the benefits of this procedure to neonatal patients. The number of patients undergoing single- and double-lung transplantation increases steadily and the indications for transplantation are being expanded. Evaluation of the early results indicates that patients undergoing lung transplantation for vascular disease do not fare as well as those undergoing transplantation for parenchymal disease. Presently, the results of retransplantation are far inferior to primary transplantation and require ongoing evaluation.
AuthorsM P Kaye (Affiliation: International Society for Heart and Lung Transplantation, UCSD Medical Center.)
JournalClinical transplants (Clin Transpl) Pg. 39-44 ( 1991) ISSN: 0890-9016 [Print] UNITED STATES
PMID1820129 (Publication Type: Journal Article)
Chemical References
  • Muromonab-CD3
Topics
  • Adolescent
  • Adult
  • Cause of Death
  • Child
  • Child, Preschool
  • Female
  • Follow-Up Studies
  • Heart Transplantation (statistics & numerical data)
  • Heart-Lung Transplantation (statistics & numerical data)
  • Humans
  • Infant
  • Male
  • Middle Aged
  • Muromonab-CD3 (therapeutic use)
  • Postoperative Complications (mortality)
  • Survival Rate
  • Transplantation, Heterotopic (statistics & numerical data)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Research Interface PRO additionally includes drill-down to evidence, articles by author, export to Excel, FDA Link and mobile subscription:
1 year subscription, $45.00 USD